- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02288169
Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial
January 4, 2017 updated by: University of South Florida
Regardless of their treatment, cancer patients endure a variety of difficult symptoms during their disease with averages ranging from 7 to 14 symptoms each.
Cancer-related symptoms, especially when symptoms are very intense, distressing, frequent, or interfere with daily activities, can lead to depression, anxiety, and diminished quality of life.
Improving their ability to self-manage difficult symptoms has the potential to diminish suffering, improve quality of life and decrease emergency room visits and associated costs.
The investigators propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients.
Objective: The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
Method: The investigators will seek 300 completed subjects, outpatients with breast, colorectal, lung, and prostate cancers.
Patients will be randomized into three groups.
Group III, the experimental group, will receive usual care plus the COPE intervention.
This group will receive 3 individual intervention sessions.
During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom.
Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home.
Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms.
In addition they will get 2 phone calls encouraging them to apply COPE.
Group II, the attention control group, will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
Group I, the control group receiving usual care, will receive no additional attention from our interventionists.
Data will be collected weekly for 9 weeks about symptoms (intensity, frequency, interference, appraisal of distress), self-efficacy, and barriers to self-management.
Patient Outcomes: Quality of life, anxiety and depression will be assessed at baseline and weeks 4, 8, and 12.
The investigators predict that the COPE group will show significant improvement in depression, anxiety, quality of life, symptom intensity, distress, frequency and interference, self-efficacy, and perceived barriers to care, as well as decreased utilization of health care resources compared with the two control groups.
Data will be analyzed using repeated measures multivariate analysis of variance using a mixed model approach.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
515
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Breast, colorectal, lung or prostate cancer patients with baseline scores on intensity, distress, and/or interference => 4 on at least 2 symptoms
- Literate in English
- Must pass mental status screening and functional status at the level of ECOG 3 or lower
Exclusion Criteria:
- patients who plan to leave Florida during the summer,
- are in hospice care, or
- confused, or
- expected to die within 3 months.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: COPE
The experimental group will receive usual care plus the COPE intervention.
This group will receive 3 individual intervention sessions.
During the first intervention visit at the cancer center, the COPE group will be taught the COPE intervention in a session focusing on the patient's self-identified most bothersome symptom.
Role modeling and additional instruction will be provided via video, and patients will receive the Home Care Guide for Cancer and a copy of the video to take home.
Three subsequent visits with the patient during regularly scheduled clinic visits will reinforce the principles of COPE and the use of the Home Care Guide, and will help patients apply this approach to managing other symptoms.
In addition they will get 2 phone calls encouraging them to apply COPE.
|
We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients.
The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
|
|
Sham Comparator: Support
The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls, matched for time with COPE participants.
|
The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
|
|
No Intervention: Control
The control group will receive usual care and no additional attention from our interventionists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of Life (The Multidimensional Quality of Life scale)
Time Frame: 13 weeks
|
The Multidimensional Quality of Life scale - Cancer will be used to assess the patient's health-related quality of life
|
13 weeks
|
|
Anxiety (State-Trait Anxiety Inventory)
Time Frame: 13 weeks
|
State Anxiety will be assessed using the State-Trait Anxiety Inventory.
|
13 weeks
|
|
Depression (The Centers for Epidemiologic Study - Depression)
Time Frame: 13 weeks
|
The Centers for Epidemiologic Study - Depression will be used to measure depressive symptoms.
|
13 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Health Services Utilization (The Health Services Utilization Index)
Time Frame: 13 weeks
|
The Health Services Utilization Index will be used to evaluate the extent to which patients seek care at the Cancer Center versus community emergency rooms.
|
13 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
July 1, 2016
Study Registration Dates
First Submitted
November 6, 2014
First Submitted That Met QC Criteria
November 10, 2014
First Posted (Estimate)
November 11, 2014
Study Record Updates
Last Update Posted (Estimate)
January 5, 2017
Last Update Submitted That Met QC Criteria
January 4, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- USflorida
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Yale UniversityNational Institute of Nursing Research (NINR); The Glimpse Group IncRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
University of Michigan Rogel Cancer CenterCompletedCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Atrium Health Wake Forest BaptistRecruitingCancer | Adolescent Cancer | Young Adult CancerUnited States
-
Vanderbilt-Ingram Cancer CenterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
Second Affiliated Hospital of Soochow UniversityNot yet recruitingCancer | Solid Cancer
-
New Mexico Cancer Research AllianceOhio State University Comprehensive Cancer Center; H. Lee Moffitt Cancer Center...RecruitingCancer | Cancer RiskUnited States
-
Children's Hospital of PhiladelphiaCompletedCancer | Childhood CancerUnited States
-
UNICANCERRecruitingAdvanced Breast Cancer | Advanced Gastric Cancer | Advanced Urothelial Cancer | Advanced Non Small Cell Lung Cancer (NSCLC)France
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
Clinical Trials on COPE
-
Duke UniversityNational Cancer Institute (NCI)CompletedAdvanced CancerUnited States
-
Duke UniversityWithdrawnCancer | Cognitive ImpairmentUnited States
-
Ohio State UniversityUniversity of South Florida; New York University; National Institute on Minority... and other collaboratorsCompletedDepression | Anxiety | Emotional Disturbances | Nutritional Deficiency | Pregnancy Late | Post-Partum DepressionUnited States
-
National Taiwan University HospitalRecruitingEducation, MedicalTaiwan
-
Ohio State UniversityAmerican Foundation for Suicide Prevention; University of San DiegoCompletedDepression | Burnout, Professional | Suicide ThreatUnited States
-
University of South FloridaRecruitingOppositional Defiant Disorder | Insomnia ChronicUnited States
-
Duke UniversityRecruitingCancer | Cognitive ImpairmentUnited States
-
Universidad Nacional de Educación a DistanciaIES Isaac NewtonCompletedDepressive Symptoms | Parental Stress | Anxiety SymptomsSpain
-
Vastra Gotaland RegionGöteborg UniversityCompleted
-
Florida International UniversityCompleted